Ian Bolland speaks to Dr Chee Yang Chen, CEO of biotech Carta Biosciences, to discuss how artificial intelligence (AI) can reverse ageing, issues surrounding drug discovery, and the pressure put on healthcare systems because of care for the elderly.
Craig Scherer - marketing director for the Insight Innovation Center at Nemera discusses how the company’s extended capabilities in front-end innovation bring new advantages for pharma customers.
Duncan Stacey, sales & marketing director at Linkam Scientific, and Sheng Qi, reader in pharmaceutics at the School of Pharmacy, University of East Anglia discuss how to improve drug-polymer miscibility analysis using a new microscopy-based method.
Here, we sit down with Ettore Cucchetti, CEO of ACG Inspection at ACG, who discusses the success of a major company milestone, and the challenges and opportunities serialisation presents.
Panna Sharma, CEO of clinical stage oncology biotech Lantern Pharma, speaks to EPM about how his company’s artificial intelligence platform could help revolutionise drug development and ultimately change the way we treat cancer.
With emerging biotechs playing a critical part in developing new drugs, Merck attempts to understand the interactions between parties when manufacturing monoclonal antibodies (mAbs).
